WELCOME TO The Biotechnology REPORT
Newsletter | Member Login | Signup
Home > Companies > Segetis Inc
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Conference
Cell and Gene Therapy
NeuExcell Therapeutics | September 13, 2021
NeuExcell Therapeutics and Spark Therapeutics, a member of the Roche Group announced a gene therapy collaboration aimed at developing a safe and effective treatment for patients suffering from Huntington's Disease (HD). Under the terms of the agreement, Spark Therapeutics will receive access to NeuExcell's proprietary neuro-regenerative gene therapy platform and capabilities. NeuExcell's research team will collaborate closely with Spark Therapeutics to advance the prog...
PR Newswire | May 15, 2020
While the COVID-19 pandemic continues to evolve, many Cancer Research Institutions and Pharma/Biotech companies are considering how to restart the biomedical research and drug development programs. This may include thinking through meeting the timeline, risk of mitigation actions, and possible program reprioritizations as components of the strategy to return to normal operations. Our preclinical services allow scientists to discover new innovative therapies effective in serious diseases without ...
IFLScience | April 09, 2020
A 60,000-year-old forest submerged in the Gulf of Mexico may hold potential for the development of new medicines and biotechnology in the future – and scientists are only just beginning to understand what other secrets it may hold. Along the banks of a river in Alabama was once a flourishing bald cypress forest. As the trees grew and died, they eventually fell and become buried in peat and sediment. Over time, sea levels rose and covered the ancient forest far beneath the surface of the oc...
Medical
Aruna Bio | June 01, 2022
Aruna Bio, Inc., a leader in the development of neural exosome based therapeutics for the treatment of neurodegenerative diseases, today announced that it has received funding from the National Institute of Neurological Disorders and Stroke of the National Institutes of Health of Health to advance AB126™, a multimodal neuroprotective and regenerative neural stem cell extracellular vesicle (NSC EV) product, to treat Traumatic Brain Injury (TBI). The succ...
Whitepaper
Medical, Industry Outlook
Video
Cell and Gene Therapy, Medical
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE